Kamada Ltd. (NASDAQ:KMDA) Short Interest Up 33.3% in December

Kamada Ltd. (NASDAQ:KMDA) was the target of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 23,200 shares, an increase of 33.3% from the December 15th total of 17,400 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average daily trading volume, of 63,600 shares, the short-interest ratio is currently 0.4 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of Kamada in a research report on Friday, January 10th.

Kamada Stock Performance

Shares of NASDAQ KMDA traded down $0.15 during midday trading on Thursday, reaching $7.09. The company’s stock had a trading volume of 79,532 shares, compared to its average volume of 245,554. The company has a market cap of $407.53 million, a P/E ratio of 25.32 and a beta of 0.98. The business’s 50 day moving average price is $6.16 and its two-hundred day moving average price is $5.74. Kamada has a fifty-two week low of $4.74 and a fifty-two week high of $8.00.

Hedge Funds Weigh In On Kamada

A hedge fund recently bought a new stake in Kamada stock. Public Employees Retirement System of Ohio purchased a new stake in Kamada Ltd. (NASDAQ:KMDA) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 14,270 shares of the biotechnology company’s stock, valued at approximately $77,000. Institutional investors and hedge funds own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.